Results 201 to 210 of about 125,674 (260)

PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation. [PDF]

Mol Cancer
Yang K, Fu K, Zhang H, Wang X, To KKW, Yang C, Wang F, Chen ZS, Fu L.   +8 more
europepmc   +1 more source

In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I. [PDF]

Molecules
Rocha KML, Nascimento ÉCM, de Jesus RCC, Martins JBL.   +3 more
europepmc   +1 more source

Correction for Kuroda et al., Bim and Bad mediate imatinib-induced killing of Bcr/Abl⁺ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. [PDF]

Proc Natl Acad Sci U S A
europepmc   +1 more source

Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies. [PDF]

J Adv Res
Sun J, Lou L, Zhu C, Chen P, Tang G, Gu M, Xia S, Dong X, Zhang ZM, Gao L, Yao SQ, Xiao Q.   +11 more
europepmc   +1 more source

The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms. [PDF]

Clin Exp Med
Huang K, Mo Q, Liao C, Feng S, Liu G, Jiang D, Lei P.   +6 more
europepmc   +1 more source

Molecular Modeling of Single- and Double-Hydrocarbon-Stapled Coiled-Coil Inhibitors against Bcr-Abl: Toward a Treatment Strategy for CML. [PDF]

J Phys Chem B
Lima MCP, Hornsby BD, Lim CS, Cheatham TE.   +3 more
europepmc   +1 more source

Concomitant L248V With E225V Mutation in the BCR-ABL Gene Associated With Rapid Chronic Myeloid Leukemia Lymphoid Blast Crisis. [PDF]

Cureus
Tungjitviboonkun S, Wachirapornpruet P, Unsuwan S.   +2 more
europepmc   +1 more source